{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:40:32Z","timestamp":1787859632805,"version":"build-2784847793"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007033","name":"Eisai Korea Inc","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00210960"],"award-info":[{"award-number":["RS-2023-00210960"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002642","name":"Korea University","doi-asserted-by":"publisher","award":["K2225581, K2424351"],"award-info":[{"award-number":["K2225581, K2424351"]}],"id":[{"id":"10.13039\/501100002642","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The widespread use of antithrombotic therapies increases bleeding risk, particularly in patients with a high bleeding risk (HBR). Although proton pump inhibitors are recommended for lowering the risk of upper gastrointestinal (UGI) bleeding, the optimal agent and dosage remain uncertain. This study evaluated the efficacy and safety of low-dose rabeprazole (LORA, 5 mg) in reducing the incidence of GI-related adverse events in HBR patients receiving chronic antithrombotic therapy. Methods: This was a prospective, multicenter, interventional study that enrolled 909 South Korean patients receiving long-term antithrombotic therapy with HBR features including age \u226570 years, dual antiplatelet therapy, combined antithrombotic regimens, and prior GI bleeding. The primary endpoint was the incidence of significant GI events, including overt\/occult bleeding and symptomatic peptic ulcer disease (PUD). Secondary endpoints included study drug discontinuation owing to GI adverse events, composite cardiovascular events, and all-cause mortality. Results: No patients had significant UGI bleeding or symptomatic PUD. The median adherence rate was 92.0% (interquartile range [IQR], 87.0\u201395.0). Drug discontinuation owing to GI symptoms occurred in 32 patients (3.52%) at a median of 81 days (IQR, 36\u2013119 days). GI-related adverse events were reported in 3.96%, with diarrhea, epigastric discomfort, and constipation being the most common. Non-GI bleeding and cardiovascular composite events occurred in 0.33% (n = 3) each, with all-cause mortality at 0.55% (n = 5). Conclusions: Low-dose rabeprazole was associated with reduced GI complications in patients receiving chronic antithrombotic therapy, with a favorable safety profile and high adherence. Further studies with larger and broader populations are required to confirm these findings.<\/jats:p>","DOI":"10.3390\/jcm15031289","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:09:41Z","timestamp":1770311381000},"page":"1289","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["LOw-Dose RAbeprazole Therapy for Reducing Gastrointestinal Events in Patients with High Bleeding Risk (LORA-HBR): A Prospective, Multicenter, Interventional Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5187-8310","authenticated-orcid":false,"given":"Dong Oh","family":"Kang","sequence":"first","affiliation":[{"name":"Cardiovascular Center, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Ung","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7101-0236","authenticated-orcid":false,"given":"Jang Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu 41944, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Joon","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju 61469, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-3274","authenticated-orcid":false,"given":"Jung-Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Cheol","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pusan National University Hospital, Pusan National University School of Medicine, Pusan 49241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0027-1420","authenticated-orcid":false,"given":"Jay Young","family":"Rhew","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Presbyterian Medical Center, Jeonju 54987, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3792-0017","authenticated-orcid":false,"given":"Jang Hyun","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Cardiology, St. Carollo Hospital, Suncheon 57931, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1264-9870","authenticated-orcid":false,"given":"Weon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul 02447, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: A population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cgh.2019.05.017","article-title":"Risk of Gastrointestinal Bleeding Increases with Combinations of Antithrombotic Agents and Patient Age","volume":"18","author":"Abraham","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention","volume":"66","author":"Giustino","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2020.05.031","article-title":"Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes with or Without PCI","volume":"76","author":"Dalgaard","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients with Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials","volume":"3","author":"Scally","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1111\/j.1440-1746.2005.04167.x","article-title":"CYP2C19 genotype and the PPIs--focus on rabeprazole","volume":"20","author":"Lim","year":"2005","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/apt.12907","article-title":"Randomised clinical trial: Prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin","volume":"40","author":"Iwakiri","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14656566.2016.1110145","article-title":"Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin\/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: A prospective, randomized, case-control study","volume":"17","author":"Liu","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e008708","DOI":"10.1161\/JAHA.118.008708","article-title":"Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores","volume":"7","author":"Natsuaki","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and\/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/MEG.0000000000001125","article-title":"Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: A systematic review and meta-analysis","volume":"30","author":"Khan","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinte.165.7.784","article-title":"Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction","volume":"165","author":"Buresly","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy-Induced Gastrointestinal Injury","volume":"79","author":"Han","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s44197-024-00267-9","article-title":"Proton Pump Inhibitor for Gastrointestinal Bleeding in Patients with Myocardial Infarction on Dual-Antiplatelet Therapy: A Nationwide Cohort Study","volume":"14","author":"Baik","year":"2024","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/MEG.0000000000000934","article-title":"Randomized clinical trial: The impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy","volume":"29","author":"Jensen","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/eurheartj\/ehz104","article-title":"Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction","volume":"40","author":"Sehested","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.31083\/j.rcm2408230","article-title":"The Efficacy and Safety of Proton Pump Inhibitors Combining Dual Antiplatelet Therapy in Patients with Coronary Intervention: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials","volume":"24","author":"Liang","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","article-title":"Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions","volume":"17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1111\/bcp.15478","article-title":"Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis","volume":"88","author":"Ahn","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.amjmed.2022.05.031","article-title":"Association of Antisecretory Drugs with Upper Gastrointestinal Bleeding in Patients Using Oral Anticoagulants: A Systematic Review and Meta-Analysis","volume":"135","author":"Kurlander","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000001284","article-title":"Efficacy and Safety of Proton Pump Inhibitors in Patients with Coronary Artery Diseases Receiving Oral Antiplatelet Agents and\/or Anticoagulants: A Systematic Review and Meta-Analysis","volume":"80","author":"Shang","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jcin.2010.12.009","article-title":"Clopidogrel and proton pump inhibitors: Influence of pharmacological interactions on clinical outcomes and mechanistic explanations","volume":"4","author":"Tantry","year":"2011","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Guo, H., Ye, Z., and Huang, R. (2021). Clinical Outcomes of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.694698"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.12698","article-title":"Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction","volume":"283","author":"Sehested","year":"2018","journal-title":"J. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ajg.2012.108","article-title":"Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis","volume":"107","author":"Kwok","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"i5813","DOI":"10.1136\/bmj.i5813","article-title":"Community acquired pneumonia incidence before and after proton pump inhibitor prescription: Population based study","volume":"355","author":"Othman","year":"2016","journal-title":"BMJ"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cgh.2023.12.022","article-title":"Reduction of Upper Gastrointestinal Bleeding Risk with Proton Pump Inhibitor Therapy in Asian Patients with Atrial Fibrillation Receiving Direct Oral Anticoagulant: A Nationwide Population-based Cohort Study","volume":"22","author":"Lee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1289\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:11:54Z","timestamp":1770613914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15031289"],"URL":"https:\/\/doi.org\/10.3390\/jcm15031289","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}